Cel­gene, Google dou­ble down on Ar­mo’s PhI­II im­muno-on­col­o­gy drug with $67M round

Ar­mo Bio­Sciences has lined up a big $67 mil­lion C round to pay for the late-stage de­vel­op­ment of some of its im­muno-on­col­o­gy as­sets.

Launched and built with the help of some mar­quee in­vestors like Cel­gene, Klein­er Perkins, GV (Google) and Or­biMed, Ar­mo has now at­tract­ed some ma­jor league Chi­nese VCs to its pipeline work. Qim­ing Ven­ture Part­ners led the round with help from new in­vestors Decheng Cap­i­tal, Se­quoia Cap­i­tal, Quan Cap­i­tal and RTW In­vest­ments. All the orig­i­nal back­ers came back in for the C round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.